Wiki BridgeTI - User contributions [en]

Cilostazol: A Comprehensive Review Of Pharmacology, Therapeutic Applications, And Clinical Evidence

2026-05-02T13:34:16Z

MargretStocks: Created page with "Cilostazol: A Comprehensive Review of Pharmacology, Therapeutic Applications, and Clinical Evidence Abstract Cilostazol, a quinolinone derivative, is a selective phosphodiesterase III (PDE3) inhibitor with unique vasodilatory, antiplatelet, and antiproliferative properties. [https://www.ft.com/search?q=Initially Initially] approved for the symptomatic management of intermittent claudication in peripheral arterial disease (PAD), its therapeutic potential has..."

Cilostazol: A Comprehensive Review of Pharmacology, Therapeutic Applications, and Clinical Evidence Abstract Cilostazol, a quinolinone derivative, is a selective phosphodiesterase III (PDE3) inhibitor with unique vasodilatory, antiplatelet, and antiproliferative properties. [https://www.ft.com/search?q=Initially Initially] approved for the symptomatic management of intermittent claudication in peripheral arterial disease (PAD), its therapeutic potential has been explored in various other cardiovascular and cerebrovascular disorders. This article provides a comprehensive review of cilostazol's mechanism of action, pharmacokinetics, established clinical applications, emerging uses, safety profile, and future research directions. 1. Introduction First synthesized in the 1980s and approved by the US Food and Drug Administration (FDA) in 1999, cilostazol has carved a distinct niche in the pharmacotherapy of vascular diseases. Unlike purely antiplatelet agents or vasodilators, cilostazol's multifaceted mechanism offers a synergistic approach to improving tissue perfusion. Its primary indication remains the improvement of maximal and pain-free walking distance in patients with intermittent claudication, a debilitating symptom of PAD. However, [https://search.yahoo.com/search?p=ongoing ongoing] research continues to elucidate its benefits in stroke prevention, coronary stent patency, and other conditions characterized by impaired blood flow. 2. Mechanism of Action and Pharmacology Cilostazol exerts its therapeutic effects primarily through the reversible inhibition of phosphodiesterase type III (PDE3), an enzyme responsible for the degradation of cyclic adenosine monophosphate (cAMP) in platelets, vascular smooth muscle cells, and cardiac tissue. The resultant increase in intracellular cAMP levels triggers a cascade of effects: Vasodilation: Elevated cAMP in vascular smooth muscle leads to relaxation and dilation of arterial beds, particularly in the peripheral vasculature, reducing peripheral resistance and increasing blood flow. Antiplatelet Activity: Increased platelet cAMP inhibits platelet aggregation induced by various stimuli (e.g., ADP, collagen, thrombin), reducing thrombotic potential. Antiproliferative Effects: Cilostazol suppresses the proliferation of vascular smooth muscle cells, a key process in restenosis following angioplasty or stent placement. Additional Effects: It modestly increases plasma levels of high-density lipoprotein (HDL) cholesterol and reduces triglycerides. Evidence also suggests it may promote endothelial repair and angiogenesis. Pharmacokinetically, cilostazol is extensively metabolized in the liver by cytochrome P450 enzymes, primarily CYP3A4 and to a lesser extent CYP2C19, into active metabolites. Its elimination is predominantly hepatic, with a half-life of approximately 11-13 hours, necessitating twice-daily dosing. Strong inhibitors of CYP3A4 (e.g., ketoconazole, erythromycin) or CYP2C19 can significantly increase cilostazol concentrations, requiring dose adjustment or avoidance. 3. Established Clinical Applications 3.1. Peripheral Arterial Disease and Intermittent Claudication The efficacy of cilostazol (typically 100 mg twice daily) in PAD is well-established through multiple randomized controlled trials (RCTs). Meta-analyses demonstrate that it increases maximal walking distance by approximately 40-50% and pain-free walking distance by approximately 50-60% compared to placebo. The improvement is attributed to both enhanced blood flow and potential improvements in skeletal muscle metabolism and endothelial function. It is considered a second-line therapy after a supervised exercise program and smoking cessation, and is contraindicated in patients with heart failure of any severity due to the class effect of PDE3 inhibitors. 3.2. Secondary Stroke Prevention While not universally approved for this indication, cilostazol has gained significant traction, particularly in East Asia, for the prevention of recurrent stroke. Large-scale RCTs, such as the CSPS.com trial, have shown that cilostazol is non-inferior or superior to aspirin in preventing recurrent cerebral infarction and carries a significantly lower risk of hemorrhagic complications. Its mechanism—combining antiplatelet action with vasodilation without increasing bleeding risk proportionally—makes it an attractive option, especially in patients at high risk for intracranial hemorrhage. 3.3. Prevention of In-Stent Restenosis The anti-proliferative property of cilostazol has been harnessed in cardiology. Studies, including several RCTs and meta-analyses, have shown that adding cilostazol to standard dual antiplatelet therapy (DAPT with aspirin and a P2Y12 inhibitor) following percutaneous coronary intervention (PCI) with stent implantation reduces the risk of in-stent restenosis and target lesion revascularization. This "triple therapy" was more commonly used with earlier-generation drug-eluting stents, but its use has declined with newer stent technologies. 4. Emerging Therapeutic Potential and Research Research continues to explore cilostazol's utility in other areas: Diabetic Complications: Investigations are ongoing into its effects on diabetic neuropathy, nephropathy, and retinopathy, potentially via improved microcirculation and anti-inflammatory actions. Subarachnoid Hemorrhage: Some evidence suggests it may reduce symptomatic vasospasm, a dangerous complication, through its vasodilatory effects. Cognitive Impairment: By improving cerebral blood flow and potentially exerting neuroprotective effects, cilostazol is being studied for vascular dementia and Alzheimer's disease. Critical Limb Ischemia: Its role as an adjunct to revascularization procedures is under investigation. 5. Safety, Tolerability, and Contraindications The most common adverse effects of cilostazol are headache, palpitations, diarrhea, dizziness, and gastrointestinal disturbances, which are often transient and dose-related. The increased cAMP in cardiac tissue explains the positive chronotropic effect (tachycardia and palpitations). The absolute contraindication is the presence of congestive heart failure of any class, stemming from the increased mortality observed with other PDE3 inhibitors (e.g., milrinone) in heart failure patients. It is also contraindicated in patients with known hypersensitivity. Caution is required in patients with severe underlying cardiac disease, those on other CYP3A4/CYP2C19 inhibitors, and those with bleeding tendencies or on concomitant anticoagulants. Its bleeding risk, while present, is generally considered lower than that of aspirin or clopidogrel. 6. Conclusion and Future Perspectives Cilostazol remains a unique agent in the vascular therapeutic arsenal. Its triple action of vasodilation, platelet inhibition, and suppression of vascular smooth muscle proliferation addresses multiple pathophysiological pathways in atherosclerotic diseases. From its cornerstone role in managing claudication to its growing evidence base in stroke prevention, cilostazol exemplifies a targeted multi-mechanistic approach. Future research directions include clarifying its role in cerebrovascular disease in Western populations, exploring its pleiotropic effects in microvascular complications of diabetes, and developing novel formulations or derivatives to enhance efficacy and minimize side effects like tachycardia. As our understanding of vascular biology deepens, cilostazol's place in therapy may continue to expand [https://rache.es/Pirfenex-Tratamiento-Antifibr%C3%B3tico-para-la-Fibrosis-Pulmonar-Idiop%C3%A1tica-Revisi%C3%B3n/ Pirfenex: Tratamiento Antifibrótico para la Fibrosis Pulmonar Idiopática] beyond its original indication.

Verapamil: A Comprehensive Study Report On Pharmacology, Clinical Applications, And Therapeutic Considerations

2026-05-02T11:05:10Z

MargretStocks: Created page with " Verapamil, a prototypical and first-generation member of the phenylalkylamine class, stands as a cornerstone in cardiovascular pharmacotherapy. Initially developed as a coronary vasodilator, its primary mechanism as a calcium channel blocker (CCB) was discovered later, cementing its role in managing a spectrum of cardiac and vascular disorders. This report provides a detailed examination of verapamil, encompassing its pharmacology, clinical applications, pharmacokine..."

Verapamil, a prototypical and first-generation member of the phenylalkylamine class, stands as a cornerstone in cardiovascular pharmacotherapy. Initially developed as a coronary vasodilator, its primary mechanism as a calcium channel blocker (CCB) was discovered later, cementing its role in managing a spectrum of cardiac and vascular disorders. This report provides a detailed examination of verapamil, encompassing its pharmacology, clinical applications, pharmacokinetics, adverse effects, and [https://www.flickr.com/search/?q=contemporary contemporary] place in therapy. 1. Pharmacological Mechanism of Action Verapamil exerts its therapeutic effects primarily by selectively inhibiting the influx of extracellular calcium ions through L-type voltage-gated calcium channels in cardiac and vascular smooth muscle cells. This inhibition is use-dependent, meaning it is more pronounced when the channels are frequently opened, as in tachyarrhythmias. In the myocardium, this results in negative chronotropy (slowing of sinus node firing rate), negative dromotropy (slowing of conduction through the atrioventricular node), and negative inotropy (reduction in contractile force). In vascular smooth muscle, calcium channel blockade leads to vasodilation, predominantly in arterial beds, reducing peripheral vascular resistance and afterload. Notably, verapamil has a greater effect on cardiac tissue compared to dihydropyridine CCBs like nifedipine, making it particularly valuable for rate control in arrhythmias. 2. Pharmacokinetics and Metabolism Verapamil is well-absorbed orally but undergoes extensive first-pass metabolism in the liver, resulting in an oral bioavailability of approximately 20-35%. It is highly protein-bound (about 90%). The drug is metabolized primarily by the hepatic cytochrome P450 enzyme system, notably CYP3A4, into numerous metabolites, with norverapamil being the most significant active metabolite. Norverapamil possesses about 20% of the cardiovascular activity of the parent compound. The elimination half-life of verapamil is single-dose is 2-8 hours, but with repeated dosing, it can extend due to saturation of first-pass metabolism. Importantly, verapamil exhibits stereoselective pharmacokinetics; the S-enantiomer is more potent in its cardiac effects. Impaired hepatic function significantly reduces clearance and necessitates dose adjustment, while renal impairment has a less pronounced effect on parent drug kinetics. 3. Clinical Applications The clinical utility of verapamil is broad, primarily within cardiovascular medicine. Cardiac Arrhythmias: This is a primary indication. Verapamil is highly effective for rate control in atrial fibrillation and atrial flutter. It is also a first-line agent for terminating and preventing recurrence of paroxysmal supraventricular tachycardia (PSVT), particularly those involving the AV node (e.g., AV nodal reentrant tachycardia). Its AV nodal blocking properties make it invaluable in these contexts. Hypertension: As an antihypertensive, verapamil reduces blood pressure through vasodilation and reduced cardiac output. It is effective as monotherapy or in combination with other agents like ACE inhibitors or thiazide diuretics. It may be preferred in patients with concomitant angina or arrhythmias. Angina Pectoris: Verapamil is used in the management of both chronic stable angina and vasospastic (Prinzmetal's) angina. It improves myocardial oxygen supply by dilating coronary arteries and reduces demand by decreasing heart rate, contractility, and afterload. Other Uses: It has been used off-label for prophylaxis of migraine headaches and cluster headaches, likely due to effects on cerebral vascular tone. It is also investigated in conditions like hypertrophic cardiomyopathy and for reducing ventricular rate in Wolff-Parkinson-White syndrome when the accessory pathway has a long refractory period (contraindicated if short refractory period). 4. Adverse Effects, Contraindications, and Drug Interactions Verapamil's adverse effect profile is largely an extension of its pharmacological actions. Common side effects include constipation (due to inhibition of calcium channels in gastrointestinal smooth muscle), dizziness, headache, peripheral edema, flushing, and bradycardia. More serious adverse effects include hypotension, exacerbation of heart failure in susceptible patients, and profound bradycardia or heart block. Absolute contraindications include sick sinus syndrome (except with a functioning pacemaker), second- or third-degree AV block (without a pacemaker), severe hypotension, cardiogenic shock, and patients with atrial fibrillation/flutter associated with an accessory pathway (e.g., WPW) with a short refractory period. It is also contraindicated in patients with severe left ventricular dysfunction and in those receiving intravenous beta-blockers. Verapamil is a substrate and moderate inhibitor of CYP3A4, leading to numerous clinically significant drug interactions. Co-administration with beta-blockers can potentiate bradycardia and heart failure. It increases plasma levels of digoxin, cyclosporine, simvastatin, and many others. Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can dramatically increase verapamil levels, while inducers (e.g., rifampin) can reduce its efficacy. Grapefruit juice inhibits CYP3A4 and should be avoided. 5. Formulations and [https://Corazondecarcar.es https://Corazondecarcar.es], Therapeutic Considerations Verapamil is available in immediate-release (IR) and sustained-release (SR) oral formulations, as well as an intravenous preparation for acute situations. The SR formulations allow for once- or twice-daily dosing, improving adherence in chronic conditions like hypertension. Intravenous verapamil is used for acute termination of PSVT or rapid rate control in atrial fibrillation. Therapeutic drug monitoring is not routinely required but may be considered in specific situations. The therapeutic range for verapamil in plasma is generally considered to be 100-400 ng/mL, though clinical response is the primary guide. Special populations require careful management: dose reduction in the elderly and those with hepatic impairment, and caution in pregnancy (Category C) and breastfeeding. 6. Place in Contemporary Therapy and Conclusion While newer CCBs and antiarrhythmic drugs have been developed, verapamil retains a vital and specific role in modern cardiology. Its unique profile of combining vasodilation with significant cardiac electrophysiological effects distinguishes it from other CCBs. It remains a drug of choice for AV nodal-dependent arrhythmias and is a valuable alternative antihypertensive, especially when a heart rate-lowering effect is desired. Its use requires a thorough understanding of its contraindications and interaction profile. In conclusion, verapamil is a versatile and potent calcium channel blocker with a well-established efficacy in managing hypertension, angina, and supraventricular arrhythmias. Its clinical application demands careful patient selection, awareness of its potential to cause cardiac conduction abnormalities, and vigilance for pharmacokinetic interactions. As a foundational agent in cardiovascular medicine, verapamil continues to be an essential tool in the therapeutic arsenal, exemplifying the principle of targeted calcium channel modulation.

User:MargretStocks

2026-05-02T11:02:30Z

MargretStocks: Created page with "I'm Derrick and I live in Los Angeles. I'm interested in Industrial and Labor Relations, Figure skating and Turkish art. I like travelling and reading fantasy. Look at my web blog Flunil: Tratamiento Eficaz para Depresión y Trastornos de Ansiedad, [https://Corazondecarcar.es https://Corazondecarcar.es],"

I'm Derrick and I live in Los Angeles. I'm interested in Industrial and Labor Relations, Figure skating and Turkish art. I like travelling and reading fantasy. Look at my web blog Flunil: Tratamiento Eficaz para Depresión y Trastornos de Ansiedad, [https://Corazondecarcar.es https://Corazondecarcar.es],